Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

The co-hosts of "The View" melted down over a new book out Tuesday on the cover-up of President Biden's decline in office, as ...

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its bankruptcy filing. The deal excludes 23andMe’s telehealth subsidiary, Lemonaid ...

Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data?

Regeneron Pharmaceuticals announced it won the bankruptcy auction for key assets of 23andMe, according to Benzinga. The $256 ...

The new owner, Regeneron Pharmaceuticals intends to continue providing 23andMe’s consumer genome services, it said.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

South San Francisco, California-based 23andMe filed for bankruptcy last month, seeking to sell its business at auction after ...

The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

U.S. District Judge Beryl Howell ruled Monday that a DOGE-lead takeover of the U.S. Institute of Peace was "unlawful" and ...

Scott Adams, the creator of the "Dilbert" comic strip, revealed Monday he is battling the same metastatic prostate cancer as ...

Regeneron Pharmaceuticals is acquiring the assets of 23andMe for $256 million, excluding its Lemonaid Health business, as the ...